Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

NCT06669572 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Squamous Cell
Anorectal Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib

Sponsor

University of Chicago